Spot on,
The reason why more diseases haven't been reported yet is purely because there hasn't yet been enough available cases to diagnose. That will come.
The price sensitivity of an 'US hospital ann' lies in the fact that the size of the US hospital(s) will give the market a reasonable gauge of the time it will take to get to the stage where we can submit the application(s) to the FDA. If we land a few hospitals that are well known whoppers, the price will climb FAST.
The faster we collect and submit results to the FDA, the faster we get to the FDA approval and the faster we become a T/O target. The bottleneck at the moment is the rate of sampling. The US hospitals effectively will turn the sampling rate tap from a dribble to a gush, and I expect the share price rise to increase accordingly.
Expect additional respiratory diseases/conditions to be added to the mix. These will form additional, seperate FDA submissions that will in time increase the functionality and scope of the ResApp.
Lastly, I don't expect the escrowed shares to be an obstacle that might cause a retrace. Considering who they are and how they relate to this stock, it is highly unlikely Uniquest will offload their escrowed shares. Plus things are only just starting to get exciting so I doubt they would be that foolish.
I may be wrong, but I believe that the strength of today's trading makes it abundantly clear that there is more than one big fish starting to gobble up shares. I said a week back that we would see some big swings. It is clear that tree shakes won't hold the price down long for too long and I think it will be a costly mistake for someone to try it again; it works best on small volume and thin buy sides, but if there are competing big funds it is suicide. So following that sort of thing, it is my experience that soon slow, steady bites will become the order of the day. A gradual climb though July suits me fine
Regards CT
(20min delay)